Globus Medical (GMED) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Globus Medical (GMED) reported robust Q2 2025 results, with revenue of $745.34 million and EPS of $0.86, both surpassing analyst consensus estimates by 0.49% and 13.16% respectively, and demonstrating significant year-over-year growth. While key segments like U.S. and International revenues, and Musculoskeletal Solutions, exceeded expectations, the Enabling Technologies segment experienced a 4.4% year-over-year decline and missed estimates. Despite the strong financial performance, GMED shares have underperformed the broader S&P 500 over the past month, and the stock currently holds a Zacks Rank #4 (Sell), indicating potential near-term underperformance.

Analysis

Globus Medical (GMED) delivered a strong financial performance in its Q2 2025 report, with revenue growing 18.4% year-over-year to $745.34 million and EPS reaching $0.86, beating consensus estimates by 0.49% and 13.16%, respectively. This growth was primarily fueled by its core Musculoskeletal Solutions division, which saw sales increase 19.8% YoY to $710.18 million, significantly outperforming analyst projections. The company demonstrated broad geographic strength, with U.S. revenues climbing 20.3% and International revenues up 11%, both exceeding estimates. However, this positive picture is contrasted by a notable weakness in the Enabling Technologies segment, where revenue declined 4.4% YoY to $35.16 million, falling short of Wall Street's expectations. This mixed operational result is mirrored in the market's reaction; despite the headline earnings beat, the stock has underperformed the S&P 500 composite by returning -7.8% over the past month and currently holds a Zacks Rank #4 (Sell), indicating potential for near-term underperformance.

Key Decisions for Investors

• Investors should recognize the fundamental strength driven by the dominant Musculoskeletal Solutions segment, which grew nearly 20% and beat estimates, serving as the primary engine for the strong earnings report.
• Careful monitoring of the Enabling Technologies division is warranted, as its 4.4% year-over-year revenue decline and missed forecast presents a significant headwind and a point of weakness in the company's growth profile.
• Given the stock's recent -7.8% underperformance and the explicit Zacks Rank #4 (Sell) rating, it is prudent to weigh the positive operational results against the prevailing negative market sentiment and potential for continued near-term pressure on the share price.